A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 658 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Taking on DNA repair to tackle cancer November 5, 2021 Football Player Scores 8 Touchdowns the Day After His Mom Dies... November 17, 2021 How to Get Started With Meditation During Cancer June 21, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... When You and Your Child Have VHL: 8 Ways to Cope EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT...
